Live market screen
Commercial Space Company Risk / Opportunity Ranking
Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.
Updated June 27, 2026
Opportunity view
Showing rows 381-400 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 381 | Star Catcher Industries, Inc. lowweak | Opp 1 Risk 2 | Thesis: There is insufficient reviewed evidence in these reviewed sources to support an opportunity thesis beyond a broad statement that the company is building space infrastructure. Why now: Why now is weak because the reviewed sources' membership rationale references article describing an orbital power grid concept, but no article or reviewed evidence are provided for ranking use. Caveats: No article is available for article. Coverage debug shows zero evidence after recent evidence window. Cannot elevate concept relevance into thesis attractiveness without direct business evidence. |
| 382 | Star Catcher Industries, Inc. lowweak | Opp 1 Risk 1 | Thesis: Reviewed evidence-level rationale suggests Star Catcher is a space startup building space-based power infrastructure, but the ranking reviewed sources provide no direct positive evidence retained inside the 90-day recent evidence window, so there is insufficient basis for a positive 1 year+ opportunity thesis from admissible evidence. Why now: Why now is weak because the company had 10 articles considered, but zero article IDs and zero evidence remained after the 90-day recent evidence window cutoff of March 29, 2026; recency-based business-state judgment is therefore unavailable from these reviewed sources. Caveats: No retained evidence after recent evidence window: articles after recent evidence window = 0 and evidence after recent evidence window = 0. Phase-2 membership rationale is not directional proof and cites support article IDs without, so it cannot be used as a fully cited factual thesis. |
| 383 | Starfighters Space lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources rationale suggests Starfighters Space has air-launch and hypersonic testing relevance, but no within the recent evidence window direct evidence or citable are present in the reviewed sources output, so that does not support a scored positive thesis here. Why now: There is no available within the recent evidence window evidence row after the March 29, 2026 cutoff; coverage data shows zero article IDs after recent evidence window and zero evidence after recent evidence window for Starfighters Space. Caveats: Phase-2 membership rationale references multiple article IDs, but the reviewed sources provide no article for citation. |
| 384 | Starfish Space lowweak | Opp 1 Risk 1 | Thesis: Membership rationale indicates autonomous proximity-operations progress, but no retained 90-day direct positive evidence is available in the served reviewed sources to support a durable upside thesis. Why now: No retained article IDs or evidence remain after recent evidence filtering, so there is no current evidence-based catalyst in the reviewed sources. Caveats: Single-article historical context is not retained within the recent evidence window. Absence of negative evidence is not positive evidence. Scoring is conservative because the current reviewed sources is effectively ungrounded for direction. |
| 385 | Starlab lowweak | Opp 1 Risk 1 | Thesis: No positive thesis is supportable because the reviewed sources retains no direct positive evidence within the recent evidence window. Why now: Why now is weak: the reviewed sources indicates zero evidence after recent evidence window, so there is no retained current catalyst or current operating-state evidence for Starlab. Caveats: Coverage after recent evidence window is empty for this company. Phase-2 membership rationale references, but no article summary or quoted evidence is included in the retained reviewed sources, so it cannot be used for factual claims here. |
| 386 | StatSat lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources does not retain sufficient company-specific positive evidence to support an opportunity thesis. Why now: The membership rationale references article and says AISSat-4 is operated by StatSat, but no retained evidence or are present after recent evidence window, leaving recency and business impact uncertain. Caveats: The only described support is a limited operational reference, not a clear catalyst. No direct dated evidence row is retained in the reviewed sources. |
| 387 | Swedish Space Corporation lowweak | Opp 1 Risk 1 | Thesis: No supported positive thesis from the retained recent evidence window evidence. The reviewed sources only notes an indirect mention of international partnerships involving Sweden in a Firefly earnings transcript summary, without clearly establishing Swedish Space Corporation's role or business impact (: no provided in reviewed sources). Why now: There is no current catalyst supported by retained evidence. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window, so recency and business-state changes cannot be assessed from these reviewed sources. Caveats: No current evidence is provided for the cited support article in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Phase2 rationale is weaker than direct company-specific event evidence and should not be treated as strong proof. |
| 388 | Swoop Technologies lowweak | Opp 1 Risk 1 | Thesis: The only reviewed sources support is review-status context that Swoop was placed among Golden Dome contract awardees for networking/simulation, which could indicate defense/space-adjacent participation, but there is no direct positive evidence row or in the reviewed sources to support a durable opportunity thesis (: not provided in reviewed sources). Why now: No inside-recent evidence window evidence are available, and the reviewed sources reports articles after recent evidence window = 0 and evidence after recent evidence window = 0, so there is no supported near-term or long-horizon timing catalyst beyond generic context. Caveats: Single-article company universe but no representative article content or provided. Contract-award framing comes only through membership rationale, not direct evidence. No materiality, scale, or timing detail is available. |
| 389 | TelePIX lowweak | Opp 1 Risk 1 | Thesis: Reviewed evidence membership rationale suggests TelePIX is a space AI solutions company partnering on a VLEO satellite mission with an optical payload, which could imply long-horizon product or mission traction, but the reviewed sources provide no retained article summaries or direct positive evidence within the 90-day recent evidence window to support a stronger opportunity case. Why now: Why now is weak because coverage data shows zero articles after recent evidence window and zero evidence after recent evidence window, so there is no current retained catalyst evidence in the last 90 days despite membership support referencing article Caveats: Support exists only in the membership rationale, which cites article: but no or article summary is provided in the reviewed sources, so it cannot be cited as a factual claim under the the evidence standard. Evidence recent evidence review shows kept_rows 0 and coverage data shows evidence after recent evidence window 0. |
| 390 | Telesat Corp lowweak | Opp 1 Risk 1 | Thesis: No retained within the recent evidence window direct positive evidence is available in the reviewed sources, so there is not enough support for an opportunity thesis despite cohort relevance. Why now: Coverage data reports zero article IDs after recent evidence window and zero evidence after recent evidence window, preventing a recency-based ranking call. Caveats: Membership rationale references satellite communications and Lightspeed progress, but no article or retained evidence are supplied for ranking use. Public company status does not itself create a thesis without evidence. |
| 391 | Terran Orbital lowweak | Opp 1 Risk 2 | Thesis: The only reviewed sources support is a membership rationale stating Lockheed's modular satellite platform leverages Terran Orbital production, which suggests manufacturing relevance, but there is no in-window company evidence to support a stronger opportunity call. Why now: There is no valid near-term or long-horizon catalyst from the reviewed sources because coverage data shows zero evidence after recent evidence window; current state cannot be confirmed from local evidence. Caveats: No evidence remained after the 90-day recent evidence window. The reviewed sources includes only sparse membership rationale, not current direct evidence. |
| 392 | TESAT lowweak | Opp 1 Risk 1 | Thesis: TESAT appears in the reviewed sources only as a partner in Kepler Communications' ESA optical communications contract. Because relations are context-only in these reviewed sources, that cannot be used as direct counterparty propagation evidence, leaving no direct positive thesis support for TESAT itself (: not provided in reviewed sources). Why now: No inside-recent evidence window direct evidence are available, so there is no supported timing argument. Caveats: Relation evidence is context-only and cannot be propagated as direct contract evidence. No or representative article summary is provided. No company-specific materiality data is available. |
| 393 | TESAT Spacecom lowweak | Opp 1 Risk 1 | Thesis: TESAT Spacecom is only referenced in prior HydRON contract context involving other companies, which is too indirect to support a positive thesis under the the evidence standard. Why now: There is no within the recent evidence window direct company evidence. Membership rationale references, but no is provided and the support level is only provisional single-article context. Caveats: Support is explicitly supporting article context, not direct company-specific event evidence. No retained evidence after recent evidence window. Relations/context-only mentions cannot be used as counterparty propagation evidence. |
| 394 | Thales lowweak | Opp 1 Risk 1 | Thesis: A weak opportunity case exists only from the phase2 rationale, which says Thales Alenia Space was linked as prime contractor for Sentinel-1 Next Generation satellites, suggesting satellite manufacturing/radar exposure. However, the reviewed sources provide no available article summaries or evidence inside recent evidence window for Thales itself, and the rationale itself questions whether subsidiary evidence should propagate to the parent. Why now: There is no citable in-recent evidence window article summary or evidence row for Thales in these reviewed sources, and coverage data shows zero article ids after recent evidence window and zero evidence after recent evidence window. Caveats: Phase2 rationale references article ids: and: but no or summaries for them are included here. Parent/subsidiary propagation is explicitly uncertain in the reviewed sources rationale. No direct evidence were available after recent evidence window. |
| 395 | Trishul Space lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources only says Trishul Space was placed in T-Hub's ORBIT spacetech accelerator context, which is not enough by itself to establish a durable positive 1 year+ thesis without direct company-specific progress evidence. Why now: There is no available within the recent evidence window evidence row after the March 29, 2026 cutoff; coverage data shows zero article IDs after recent evidence window and zero evidence after recent evidence window for Trishul Space. Caveats: Phase-2 membership rationale references article: but the reviewed sources provide no for citation. Accelerator participation context is weaker than direct commercial, funding, or technical milestone evidence. |
| 396 | True Anomaly Centennial lowweak | Opp 1 Risk 1 | Thesis: Potential long-horizon opportunity cannot be established from available evidence. The reviewed sources membership rationale says the company was selected in the U.S. Space Force Andromeda contract for space surveillance, but no direct within the recent evidence window evidence or article details are available for scoring. Why now: Why-now visibility is weak because the reviewed sources show zero evidence kept after recent evidence window for this company, so any claimed contract relevance lacks scoreable supporting detail in the current batch. Caveats: Reviewed evidence cites: in membership rationale but does not provide article summary or available evidence, so it cannot be used as direct scoring evidence. Coverage debug shows articles after recent evidence window 0 and evidence after recent evidence window 0. Absence of negative evidence is not positive evidence. |
| 397 | ULA lowweak | Opp 1 Risk 1 | Thesis: ULA is identified as a launch provider in membership context, but the reviewed sources retains no 90-day positive evidence to support an investable long-horizon opportunity view. Why now: Coverage data shows zero retained article IDs and evidence after the recent evidence filter, so there is no recent thesis-driving evidence in the reviewed sources. Caveats: Only membership-level context is present in the served reviewed sources. No direct event, fact, or article-context evidence remains within the recent evidence window. Direction cannot be inferred from category membership alone. |
| 398 | Uncovr lowweak | Opp 1 Risk 1 | Thesis: A funding-roundup mention suggests some financing activity, but the reviewed sources have no usable direct positive evidence after recent evidence window and does not connect the company to a space-specific thesis. Why now: The only described context is a funding-roundup article referenced in phase2 rationale, but no post-recent evidence window evidence or are provided for thesis use. Caveats: Phase2 rationale says Uncovr was listed as having raised $7M in article: but no was provided in the reviewed sources. Despite support_counts mentioning dated event/facts, the company-level available evidence arrays are empty and coverage data shows evidence after recent evidence window = 0. Broad funding roundup context is weaker than direct company-specific event evidence. |
| 399 | United Launch Alliance lowweak | Opp 1 Risk 1 | Thesis: Insufficient admissible reviewed sources evidence to support a positive thesis within the 90-day recent evidence window, despite membership rationale identifying ULA as a rocket company tied to Vulcan and Atlas V contexts. Why now: Why now is unsupported because the reviewed sources contain no surviving article or evidence after the selected recent evidence window; business-state or catalyst timing cannot be judged from the provided materials. Caveats: Zero evidence survived after recent evidence filtering. Company membership in the cohort is not thesis attractiveness. No dated catalyst, performance update, or direct risk item is included. |
| 400 | Univity lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources indicates Univity is a satellite startup that raised capital and plans a large VLEO constellation, but no dated within the recent evidence window evidence or article summaries are available here to support a stronger positive thesis. Why now: No usable within the recent evidence window evidence were available after filtering; recency-based thesis formation is therefore not supported in these reviewed sources. Caveats: Coverage after recent evidence window is effectively empty in these reviewed sources. Membership rationale is not directional proof. |
Risk view
Showing rows 141-160 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 141 | Cosmoserve Space lowweak | Opp 2 Risk 2 | Thesis: Risk is mainly early-stage execution uncertainty and limited evidence depth: only two articles considered and zero available evidence after recent evidence window. Why now: Why now is weak because the reviewed sources does not establish current demo timing or funding status with direct evidence after recent evidence window. Caveats: Private company with thin visible evidence in these reviewed sources. Mission/demo status cannot be validated from available evidence. |
| 142 | D-Orbit lowweak | Opp 3 Risk 2 | Thesis: The main risk is evidentiary: the reviewed sources lack strong recent company-specific event/facts within the recent evidence window, limiting confidence on current execution state. Why now: Why-now is weak because retained evidence after recent evidence window is mostly undated context; one cited article is from February 14, 2026 and therefore outside the 90-day evidence window, while the remaining available context is undated. Evidence
Caveats: Reviewed evidence membership rationale mentions a €119 million ESA contract, but no citeable retained row for that contract is included here. Series D funding mention is in a February 14, 2026 article outside the 90-day recent evidence window. Undated context is not recency proof. |
| 143 | Dhruva Space lowweak | Opp 4 Risk 2 | Thesis: The risk is that none of the cited grant or partnership evidence is actually available into the kept post-recent evidence window evidence set, so durability, funding size, execution status, and commercial conversion remain unverified in the reviewed sources. Why now: The reviewed sources references: and: in the membership rationale, suggesting relatively recent strategic developments, but the coverage report still shows zero evidence after recent evidence window, so timing confidence is limited. Caveats: Positive thesis relies on membership rationale, not available direct evidence. Partnership evidence cannot be expanded through relation propagation beyond what is explicitly stated. |
| 144 | EarthDaily lowweak | Opp 1 Risk 2 | Thesis: Main risk in these reviewed sources is evidence absence rather than a documented business setback. With no available within the recent evidence window direct positive or negative evidence, visibility into current traction, financing, or execution is poor. Why now: Why now is weak because the reviewed sources show zero evidence kept within the 90-day recent evidence window for ranking, making recency and business-state assessment uncertain. Caveats: Phase-2 membership rationale references: but no or available evidence row is provided in these reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Cannot treat cohort membership as thesis attractiveness. |
| 145 | ElevationSpace mediummedium | Opp 6 Risk 2 | Thesis: Risk is mostly normal scale-up and execution risk from pursuing ambitious transportation and recovery-platform goals; the reviewed sources does not provide direct negative evidence such as delays, litigation, or financing stress. Why now: The catalyst is recent and dated: the financing article is timestamped June 19, 2026, which is inside the 90-day recent evidence window and recent enough to matter for a 1 year+ business-building horizon. Evidence
Caveats: Support is still supporting article context rather than direct positive events. Only one article is available, limiting corroboration. |
| 146 | Eta Space lowweak | Opp 4 Risk 2 | Thesis: The reviewed sources does not provide material negative evidence, but development and mission-execution risk remain implicit because the thesis rests on a demonstration mission rather than proven commercial scale. Why now: The membership rationale specifically points to the LOXSAT mission demonstration as the current relevance driver, citing article: but the reviewed sources does not include the article or more detailed dated evidence fields. Caveats: Underlying article is not provided in the reviewed sources. Score is based on membership rationale summary rather than available direct evidence. Single-mission validation is weaker than broad commercial traction. |
| 147 | Exquadrum, Inc. lowweak | Opp 2 Risk 2 | Thesis: The evidence is minimal and mostly acquisition context rather than direct company-specific operating evidence. Without retained post-recent evidence window detail, there is no basis for a stronger opportunity or risk call, and ownership/status changes may have already altered standalone operating exposure. Why now: No retained evidence establishes current milestone timing or post-acquisition integration progress, so there is no strong why-now supported in these reviewed sources. Caveats: No current evidence is provided for the cited support article in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Acquisition context is weaker than direct operating evidence. |
| 148 | Fergani Space lowweak | Opp 2 Risk 2 | Thesis: The main risk is evidentiary uncertainty: there is no available direct adverse evidence, but there is also no post-recent evidence window operating, financing, customer, or execution evidence to confirm momentum. Why now: There is no credible 'why now' catalyst in the reviewed sources because articles after recent evidence window and evidence after recent evidence window are both zero for this company. The only cited support is older or excluded from the active evidence set: article, referenced in the membership rationale, was outside the kept recent evidence window according to the company coverage report. Caveats: No evidence were available after recent evidence filtering. No representative articles or additional_company_articles were provided. Membership rationale is weaker than direct event/fact evidence. |
| 149 | Firefly Aerospace lowweak | Opp 4 Risk 2 | Thesis: The evidence is limited to one recent article-level source and does not provide strong company-specific downside evidence, so risk stays low but uncertainty remains high. Why now: A dated May 26, 2026 article puts a fresh NASA program win into the current evidence window, which can matter over a 1 year+ horizon even if revenue realization is later. Evidence
Caveats: Only one within the recent evidence window article is available. Evidence is supporting article context rather than stronger extracted direct events. Timing of mission realization is long-dated relative to the evidence window. |
| 150 | GalaxEye Space lowweak | Opp 2 Risk 2 | Thesis: Risk is mainly lack of current evidentiary confirmation rather than documented business trouble. Why now: There is no within the recent evidence window evidence available in these reviewed sources for GalaxEye Space; timing and maturity of current milestones cannot be confirmed from reviewed sources evidence. Caveats: Membership rationale cites article IDs and, but their article content is not provided here for citation. Evidence recent evidence review shows 0 kept rows. This entity may overlap with GalaxEye Space Solutions Private Ltd, but the output contract requires scoring both separately. |
| 151 | GalaxEye Space Solutions Private Ltd lowweak | Opp 1 Risk 2 | Thesis: Risk is mainly evidence uncertainty rather than documented adverse developments, because no direct negative evidence or current operating milestones were available after the recent evidence filter. Why now: There is no within the recent evidence window evidence available for this entity in the reviewed sources; recency of any business progress is uncertain. Caveats: Evidence recent evidence review shows 0 kept rows after the 90-day cutoff for this entity. Membership rationale references article IDs, and: but no article summaries or direct evidence are included in these reviewed sources for citation-level use. Scores are constrained by absence of directional evidence, not by a proven negative business outcome. |
| 152 | GalaxySpace lowweak | Opp 3 Risk 2 | Thesis: No material adverse evidence is present, but the evidence is too limited and research-oriented to reduce uncertainty materially. Why now: The reviewed sources references article: for the research institute setup, yet does not provide the article or direct event details to assess timing or commercial conversion. Caveats: Only one article is considered and no representative article object is provided. Research institute formation is weaker than product, contract, or financing milestones. Commercial impact timing is unclear. |
| 153 | GALVANY lowweak | Opp 2 Risk 2 | Thesis: The same evidence creates moderate execution/classification risk: the company may have financing momentum, but the reviewed sources does not establish that it fits the target cohort or that the funding translates into durable business opportunity. No direct adverse event is available. Why now: The only possible timing angle is the referenced seed raise in the membership rationale, but no -backed available evidence remains after the recent evidence filter, so recency and impact cannot be validated for scoring. Caveats: Membership rationale references article ID: but no is provided in the reviewed sources, so it cannot be cited as factual scoring evidence under the the evidence standard. Funding context does not prove target-cohort fit. |
| 154 | Gate Space lowweak | Opp 3 Risk 2 | Thesis: Risk is modest because the evidence base is only one undated, supporting article context with no direct company events beyond funding context, making current status and durability uncertain Why now: For a 1 year+ horizon, funding can matter, but recency is uncertain because the article is explicitly undated and the reviewed sources say undated external evidence is relevance context rather than recency proof Evidence
Caveats: The evidence is weak context and supporting article context, not direct structured company event/fact evidence. The article is undated; the reviewed sources explicitly says recency-sensitive claims should be treated cautiously. Same-article repeated rows are not independent confirmation. |
| 155 | General Atomics mediummedium | Opp 6 Risk 2 | Thesis: The main risk is evidentiary rather than operational: the reviewed sources contain no direct negative evidence, but also no company-specific contract value, backlog, execution milestone, or follow-on detail. The Andromeda item is supporting article context and same-article repeats are not independent confirmation, so the opportunity could be overstated if General Atomics' role is small or non-recurring., April 8, 2026 Why now: The catalyst is recent within the reviewed sources recent evidence window: the is April 8, 2026, and it describes Space Force awarding Andromeda contracts, a potentially durable procurement cycle relevant to a 1 year+ horizon., April 8, 2026 Evidence
Caveats: This is supporting article context/weak context, not a direct company event row. Same-article repeated rows in the reviewed sources are not independent confirmation. |
| 156 | GEOST lowweak | Opp 2 Risk 2 | Thesis: The main risk is lack of current standalone visibility: because evidence appears tied to acquired-business context and no retained rows are included, current operating status, ownership implications, and commercial significance cannot be established from these reviewed sources. Why now: There is no retained within the recent evidence window evidence. Any thesis would rely on older context referenced in the membership rationale, which is insufficient for a stronger rank. Caveats: Reviewed evidence references acquired-business context rather than current standalone operations. No representative articles or retained evidence are included. Low scores reflect missing timely evidence, not a directional call on the business. |
| 157 | GHGSat lowweak | Opp 2 Risk 2 | Thesis: Risk appears limited based on the reviewed sources only because there is no adverse evidence, but confidence is low since there is also no direct traction, contract, funding, or milestone evidence available. Why now: The reviewed sources offers no recent evidence window-supported event timing for a why-now view. Caveats: The membership rationale says GHGSat is the world's leading commercial greenhouse gas monitoring satellite company, but the supporting article content is not available here for ranking use. Absence of negative evidence is not positive evidence. |
| 158 | Globalstar lowweak | Opp 2 Risk 2 | Thesis: There is no direct adverse evidence in the reviewed sources; risk is limited to uncertainty from missing current evidence rather than any documented deterioration. Why now: No within the recent evidence window evidence were available for Globalstar in these reviewed sources, so there is no current catalyst basis to elevate either opportunity or risk. Caveats: Evidence recent evidence review shows 0 kept rows after the 90-day cutoff. Membership rationale cites article IDs, and: but those article contents are not provided here for direct factual citation. Public company status does not improve ranking without directional evidence. |
| 159 | Guodian Gaoke lowweak | Opp 5 Risk 2 | Thesis: No direct negative evidence is shown; key risk is uncertainty around monetization, expansion beyond Phase I, and lack of corroborating direct evidence in the reviewed sources. Why now: The why-now would be the reported trial license and completed Phase I constellation, but the reviewed sources does not provide the underlying article summary or date-specific evidence for stronger timing confidence. Caveats: Phase2 membership rationale references: but no summary/evidence row is available to cite directly. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Score exceeds Beijing Guodian High-Tech slightly because rationale mentions both licensing and constellation completion. |
| 160 | Guoxing Aerospace Technology lowweak | Opp 2 Risk 2 | Thesis: The reviewed sources also says the company-specific operating category is not clearly established from the provided evidence alone. That uncertainty, plus the lack of retained direct evidence, limits confidence in any positive thesis. Why now: Space-based AI computing could be strategically relevant over 1 year+, but the reviewed sources provide no retained dated evidence to confirm partnership scope, timing, or commercial milestones. Caveats: No current evidence is provided for the cited support article in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Partnership mention alone is insufficient to prove durable company impact. |